Hikma Pharmaceuticals Share Discussion Threads

[modform] 19/5/2015 11:52

Good solid company, I have been buying dips in the past few days..

[broadwood] 18/5/2015 13:09

Shares in Hikma Pharmaceuticals were under pressure on Monday, down 2% after the company said its founder and major shareholder, Samih Darwazah, passed away last Friday at the age of 85.
Hikma floated on the London Stock Exchange in 20105 and entered the FTSE 100 index in March 2015, replacing Tullow Oil.

Darwazah founded Hikma in 1978 in Amman, Jordan, with the aim of bringing high-quality and affordable medicines to the world. With the help of his children, who joined the business in its early days, Hikma grew from a small factory in Jordan into the largest regional supplier of pharmaceuticals in the Middle East and North Africa.

The company also expanded outside the MENA region, establishing successful operations in Europe and the United States. Today, it operates in around 50 countries, selling a broad range of branded generics, generic injectables, non-injectable generics and in-licensed patented products.

[broadwood] 14/5/2015 09:26

Hikma Pharmaceuticals said it had enjoyed a good start to the year and said revenues at its Injectables division would remain at a similar level to last year's but with a slight decline in operating profit margins.
Ahead of its annual shareholder meeting on Thursday, the FTSE 100 group reiterated its overall full year guidance of 6% revenue growth in constant currency, with currency fluctuations would flatten turnover growth to just 2% at the reported levels.

Currently the consensus forecast for full year adjusted profit before tax stands at around $374m.

Hikma said first half revenues were likely to be flat against the extremely strong performance last year, with the second half providing the expected bulk of revenue growth for the full year.

[broadwood] 12/5/2015 14:38

Hikma Pharmaceuticals on Tuesday launched a caffeine citrate injection to treat apnea resulting from prematurity in infants of between 28 and 33 weeks of gestational age.
The company noted that sales of caffeine citrate injections in the US last year were of $7.6m.

Chairman and chief executive Said Darwazah said: "This is our first launch from the Bedford portfolio acquired last year.

"We are making good progress in the transfer of the Bedford products to our manufacturing facilities and this launch demonstrates our strong R&D, regulatory and manufacturing capabilities

[coppertrader] 22/4/2015 12:15

The mylan news is worth a read. They appear to be buying out other generics drug companies to grow so that they can not be brought out by teva. Interesting times

[r ball] 22/4/2015 05:36

read across from Mylan?

[johnthespacer] 17/4/2015 12:56

Proposed final dividend of 15.0 cents per share (22.0 cents per share for the full year), plus a special dividend of 6.0 cents per share (10.0 cents per share for the full year), making a total combined dividend for the year of 32.0 cents per share

[johnthespacer] 17/4/2015 12:37

Ex dividend on 16/04/15 so this is part of the drop reason... i must look to see how much we are getting this time

[megordon] 16/4/2015 15:43

Went long earlier today, hoping this is a double bottom and ready for a bit of a bounce now.

GLA.

[stats11] 02/4/2015 18:53

Prime Takeover target.

[r ball] 01/4/2015 20:02

why the money?

[rosieoutlook] 23/3/2015 12:35

From FT March 13th: Hikma Pharmaceuticals was down 5.3 per cent to £22.31 after Citi analysts speculated about a possible bid for Roxane Laboratories, the $2.4bn-valued US generic drugmaker owned by Boehringer Ingelheim.

Presumably the reason for requiring the bond.

[blackswan23] 23/3/2015 09:12

Broadwood- thanks for information regarding Hikma releasing bonds in a re financing initiative. I've been looking around for some time for some information as to why my Hikma shares are losing value. I'm holding on for their promotion to the FTSE 100. Can only wonder what the big need for refinancing is.

[r ball] 17/3/2015 19:57

Ps: sorry I have thrown it out. Don't have further details.

[coppertrader] 17/3/2015 18:26

Whats the cash needed for? Any ideas?

[broadwood] 17/3/2015 16:20

Middle East focused Hikma Pharmaceuticals is reportedly planning to sell its first benchmark-sized dollar bonds, according to two people familiar with the sale.
Bloomberg News on Tuesday cited sources close to the deal in its report. Shares in Hikma fell 1.8% to 2217p on the back of the report, as market participants sought to ascertain the driver behind the company's need to raise capital.

Analysts think it may have to do with recent news over the FTSE Group announcing at its quarterly reshuffle that Hikma will be promoted into the UK's FTSE 100 Index of London leading shares on March 24. The stock is currently located in the FTSE 250 Index together with a listing in NASDAQ Dubai.

Hikma was founded in Jordan in 1978 and develops and manufactures a range of branded and non-branded drugs for US and European markets but with a focus on the Middle East and North Africa.

According to Bloomberg's report, Hikma has selected Barclays, Citigroup, HSBC and National Bank of Abu Dhabi to manage the sale of its first benchmark bond which may have a tenor of five years, say sources.

Benchmark-sized bonds tend to raise at least $500m when issued in the market. Bond issuances in the Middle East and North Africa rose 78% to $9.3bn this year, according to data compiled by Bloomberg, as issuers flood the market before the Federal Reserve starts its rate hiking measure, expected this year.

According to Bloomberg, Hikma, Barclays, Citigroup and National Bank of Abu Dhabi all declined to comment and a spokesman for HSBC couldn't immediately be reached

[pyemckay] 05/3/2015 17:01

This is very highly rated now and there is no room for any misses on growth or earnings.
Forward p/e 27. I am looking for an aquisition soon as forecast growth isnt as strong as I would like.


I still hold but will re-evalute very soon.

[karateboy] 03/3/2015 17:23

From my experience, share price prior to being upgraded to Ftse 100 always goes up on institutional investors taking a position. Following confirmation , share price settles down until good news come along. I believe that is just what is happening.